Confo Therapeutics SA
59.0 FTEConfo Therapeutics reported revenue of 176,727 € for the 2025 financial year (annual accounts filed with the NBB on 08 Jun 2026), with 59 full-time equivalents.
The score of Confo Therapeutics shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Revenue -65 % Total assets +179 % Headcount (avg FTE) +2 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Confo Therapeutics's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 176,727 € | ||||
| Net result | −€17.4m | ||||
| Equity | €33.3m | ||||
| Cash | €6.16m | ||||
| EBITDA | −949,199 € | ||||
| Total assets | €37.8m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 08 Jun 2026
- Year ended 31 Dec 2024filed on 12 Jun 2025
- Year ended 31 Dec 2023filed on 17 Jul 2024
- Year ended 31 Dec 2022filed on 05 Jun 2023
- Year ended 31 Dec 2021filed on 04 Jul 2022
Confo Therapeutics's financial analysis
- Solvency88.1%sector median: 61.7%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Confo Therapeutics
Confo Therapeutics's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0632.474.939
- VAT number
- BE0632474939
- Peppol
- Registered · 0208:0632474939 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 11 Jun 2015
- Registered office
- 9052 Ghent
- Size
- Medium · 59.0 FTE
- Latest accounts
- 2025 · filed on 08 Jun 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Confo Therapeutics (SA) has been based in Ghent since 2015, active in: research and experimental development on biotechnology. For 2025, it reports revenue of 176,727 €, a net loss of €17.4m and equity of €33.3m. With 59.0 full-time equivalents, it is a medium-sized enterprise by headcount. Its solvency stands at 88.1%, above the median of its sector (61.7%).
Guide: Checking a Belgian supplier invoice: numbers and IBAN →
Companies similar to Confo Therapeutics
Companies in the same business, of comparable size and area, outside its group.
- Augustine Therapeutics Research and experimental development on natural sciences and engineering Leuven · balance sheet €30.9m
- iTeos Belgium Research and experimental development on natural sciences and engineering Charleroi · balance sheet €46.3m
- Biotalys Research and experimental development on natural sciences and engineering Ghent · balance sheet €16.3m
- Nanocyl Research and experimental development on natural sciences and engineering Sambreville · balance sheet €13.2m
- The Oncidium Foundation Research and experimental development on natural sciences and engineering Auderghem · balance sheet €60.5m
- OSIVAX Belgique Research and experimental development on natural sciences and engineering Liège · balance sheet €17.0m
- The Akkermansia Company Research and experimental development on natural sciences and engineering Mont-Saint-Guibert · balance sheet €16.9m
- Devgen Research and experimental development on natural sciences and engineering Ghent · balance sheet €130.9m
Frequently asked questions about Confo Therapeutics
What is the revenue of Confo Therapeutics?
According to the 2025 annual accounts filed with the NBB, the revenue of Confo Therapeutics amounts to 176,727 €.
What is the VAT number of Confo Therapeutics?
In Belgium, the VAT number is the company number prefixed with BE: BE0632474939 for Confo Therapeutics, if the company is VAT-registered. Its company number (CBE) is 0632.474.939.
Where is the registered office of Confo Therapeutics?
According to the CBE register, the registered office of Confo Therapeutics is in 9052 Ghent.
What is the equity of Confo Therapeutics?
At the close of the 2025 financial year, the equity of Confo Therapeutics amounts to 33,287,463 €, a solvency of 88.1% of total assets.
How many people work at Confo Therapeutics?
59.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Confo Therapeutics?
The register lists 15 active mandates at Confo Therapeutics. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Confo Therapeutics
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →